X4 Pharmaceuticals, Inc — Capital/Financing Update 2021

Jul 7, 2021

CORRESP 1 filename1.htm html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk Copyright 2021 Workiva Document

X4 Pharmaceuticals, Inc.

61 North Beacon Street, 4 th Floor

Boston, MA 02134

July 7, 2021

Via Edgar

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jeffrey Gabor

RE: X4 Pharmaceuticals, Inc.

Registration Statement on Form S-3

File No. 333-257422

Acceleration Request

Requested Date: July 9, 2021

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257422) (the “ Registration Statement ”) to become effective at 4:00 p.m. Eastern Time on Friday, July 9, 2021, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.

[ Signature page follows ]

Sincerely,

X4 Pharmaceuticals, Inc.

By: __ /s/Adam S. Mostafa

Adam S. Mostafa

Chief Financial Officer

cc: Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc.

Derek Meisner, General Counsel, X4 Pharmaceuticals, Inc.

Daniel I. Goldberg, Cooley LLP

Courtney T. Thorne, Cooley LLP